IL‐22 and IL‐22 binding protein (IL‐22BP) regulate fibrosis and cirrhosis in hepatitis C virus and schistosome infections
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Interleukin (IL)‐22 acts on epithelia, hepatocytes, and pancreatic cells and stimulates innate immunity, tissue protection, and repair. IL‐22 may also cause inflammation and abnormal cell proliferation. The binding of IL‐22 to its receptor is competed by IL‐22 binding protein (IL‐22BP), which may limit the deleterious effects of IL‐22. The role of IL‐22 and IL‐22BP in chronic liver diseases is unknown. We addressed this question in individuals chronically infected with schistosomes or hepatitis C virus (HCV). We first demonstrate that schistosome eggs stimulate production of IL‐22 transcripts and inhibit accumulation of IL22‐BP transcripts in schistosome‐infected mice, and that schistosome eggs selectively stimulate production of IL‐22 in cultures of blood leukocytes from individuals chronically infected with Schistosoma japonicum. High IL‐22 levels in cultures correlated with protection against hepatic fibrosis and portal hypertension. To test further the implication of IL‐22/IL‐22BP in hepatic disease, we analyzed common genetic variants of IL22RA2, which encodes IL‐22BP, and found that the genotypes, AA, GG of rs6570136 (P = 0.003; odds ratio [OR] = 2), and CC, TT of rs2064501 (P = 0.01; OR = 2), were associated with severe fibrosis in Chinese infected with S. japonicum. We confirmed this result in Sudanese (rs6570136 GG [P = 0.0007; OR = 8.2], rs2064501 TT [P = 0.02; OR = 3.1]), and Brazilians (rs6570136 GG [P = 0.003; OR = 26], rs2064501 TC, TT (P = 0.03; OR = 11]) infected with S. mansoni. The aggravating genotypes were associated with high IL22RA2 transcripts levels. Furthermore, these same variants were also associated with HCV‐induced fibrosis and cirrhosis (rs6570136 GG, GA [P = 0.007; OR = 1.7], rs2064501 TT, TC (P = 0.004; OR = 2.4]). Conclusions: These results provide strong evidence that IL‐22 protects against and IL‐22BP aggravates liver fibrosis and cirrhosis in humans with chronic liver infections. Thus, pharmacological modulation of IL‐22 BP may be an effective strategy to limit cirrhosis. (H epatology 2015;61:1321–1331)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liang, S. C., Tan, X.-Y., Luxenberg, D. P., Karim, R., Dunussi-Joannopoulos, K., Collins, M., & Fouser, L. A. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20061308 · Cited by 2,330 · cited 1×
“lL-22 also stimulates production of antimicrobial peptides that limit the invasion of microbes across epithelial lesions.(2,6,7,11) Schistosome eggs perforate the intestinal wall; therefore, epithelial lesions caused by eggs, which allow the entry of bacteria and toxic bacterial products, Table 3.”
Boniface, K., Bernard, F.-X., Garcia, M., Gurney, A. L., Lecron, J.-C., & Morel, F. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.6.3695 · Cited by 864
Nograles, K. E., Zaba, L. C., Shemer, A., Fuentes-Duculan, J., Cardinale, I., Kikuchi, T., Ramon, M., Bergman, R., Krueger, J. G., & Guttman-Yassky, E. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.03.041 · Cited by 627 · cited 1×
“This suggests that IL-22 is probably produced by Th22 cells (23, 24) and NK-like innate”
Interleukin-22 induces hepatic stellate cell senescence and restricts liver fibrosis in mice
Kong, X., Feng, D., Wang, H., Hong, F., Bertola, A., Wang, F.-S., & Gao, B. (2012) · Hepatology · doi:10.1002/hep.25744 · Cited by 448
IL-22 is involved in liver regeneration after hepatectomy
Ren, X., Hu, B., & Colletti, L. M. (2010) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00075.2009 · Cited by 109
Cited by
Immunology in the liver — from homeostasis to disease
Heymann, F., & Tacke, F. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2015.200 · Cited by 1,180
P2X1-regulated IL-22 secretion by innate lymphoid cells is required for efficient liver regeneration
Kudira, R., Malinka, T., Kohler, A., Dosch, M., de Agüero, M. G., Melin, N., Haegele, S., Starlinger, P., Maharjan, N., Saxena, S., et al. (2016) · Hepatology · doi:10.1002/hep.28492 · Cited by 50
“In the liver, IL-22 acts on hepatocytes and stellate cells and exhibits hepatoprotective properties by reducing liver fibrosis and ameliorating acute liver injury.((2-5)) In response to partial hepatectomy (PH), levels of IL-22 are elevated in the regenerating liver and exogenous administration of IL-22 as well as tra…”
BackgroundThe role of IL‐22 in the resolution of sterile and nonsterile inflammation
Alabbas, S. Y., Begun, J., Florin, T. H., & Oancea, I. (2018) · Clinical & Translational Immunology · doi:10.1002/cti2.1017 · Cited by 37
“blocking agents or induction of IL-22-producing cells.(67,79,102,132,135) Other approaches include developing small molecule agonists of the aryl hydrocarbon receptor to enable the activation of”
BackgroundInfluential
Metadata
- Authors
- Sertorio, M., Hou, X., Carmo, R. F., Dessein, H., Cabantous, S., Abdelwahed, M., Romano, A., Albuquerque, F., Vasconcelos, L., Carmo, T., Li, J., Varoquaux, A., Arnaud, V., Oliveira, P., Hamdoun, A., He, H., Adbelmaboud, S., Mergani, A., Zhou, J., Monis, A., Pereira, L. B., Halfon, P., Bourlière, M., Parana, R., dos Reis, M., Gonnelli, D., Moura, P., Elwali, N. E., Argiro, L., Li, Y., & Dessein, A.
- Venue
- Hepatology
- Published
- 2015-03-10
- Volume
- 61
- Issue
- 4
- Pages
- 1321-1331
- ISSN
- 0270-9139 (ISSN-L)
- 1527-3350
- OpenAlex
- W2086757562
- Cited by
- 78
- References
- 5
- FWCI
- 6.30
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.